[Clinical studies with a new antihypertensive agent, Bendigon].
D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D004232:Diuretics / Q000627:therapeutic use; D004338:Drug Combinations; D004357:Drug Synergism; D005069:Evaluation Studies as Topic; D005663:Furans / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007294:Inositol / Q000627:therapeutic use*; D008529:Mefruside; D008875:Middle Aged; D009539:Nicotinic Acids / Q000627:therapeutic use*; D012110:Reserpine / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D004232:Diuretics; D004338:Drug Combinations; D005663:Furans; D009539:Nicotinic Acids; D013449:Sulfonamides; C000242:inositol nicotinate, mefruside, reserpine drug combination; D007294:Inositol; D012110:Reserpine; D008529:Mefruside
Klinische Prüfung des neuen Antihypertonikums Bendigon.